Polynucleotide encoding cytokine receptor zcytor17 multimer

• US 7,494,804 B2
• Filed: 01/21/2003
• Issued: 02/24/2009
• Est. Priority Date: 01/18/2002
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Dillon, Stacey R., Gao, Zeren, Novak, Julia E., Presnell, Scott R., Gross, Jane A., Sprecher, Cindy A., Whitmore, Theodore E., Hammond, Angela K., Grant, Francis J., Kuijper, Joseph L., Dasovich, Maria M.
• Primary Examiner(s): Bunner; Bridget E.
• Assistant Examiner(s): Hamud; Fozia M
• Application Number:
  US10/351,157
• Publication Number:
  US 20030215838A1
• Time in Patent Office: 2,226 Days
• Field of Search: None
• US Class Current: 435/69.52
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 39/02 : Antidotes
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/52 : Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 14/715 : for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 16/2866 : against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Claims

1. An expression vector comprising the following operably linked elements:

a) a first transcription promoter;

a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 20–

732 of SEQ ID NO;

111; and

a first transcription terminator, and

b) a second transcription promoter;

a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28–

979 of SEQ ID NO;

7; and

a second transcription terminator;

wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and

wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27–

164 of SEQ ID NO;

2.

2. A cultured cell comprising the expression vector of claim 1, wherein the cell expresses the first cytokine receptor polypeptide and the second cytokine receptor polypeptide encoded by the DNA segments.

3. A method of producing a multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 2; and

isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

4. A cultured cell comprising:

a first expression vector comprising;

a) a first transcription promoter;

b) a first DNA segment encoding a first cytokine receptor polypeptide comprising amino acid residues 20–

732 of SEQ ID NO;

111; and

c) a first transcription terminator; and

a second expression vector comprising;

a) a second transcription promoter;

b) a second DNA segment encoding a second cytokine receptor polypeptide comprising amino acid residues 28–

979 of SEQ ID NO;

7; and

c) a second transcription terminator;

wherein the first cytokine receptor polypeptide and the second cytokine receptor polypeptide form a multimeric or heterodimeric cytokine receptor; and

wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising amino acid residues 27–

164 of SEQ ID NO;

2.

6. A method of producing a multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 4; and

isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

5. A method of producing an antibody to a soluble multimeric or heterodimeric cytokine receptor comprising a first cytokine receptor polypeptide consisting of amino acid residue 20 to amino acid residue 519 of SEQ ID NO:

111 and a second cytokine receptor polypeptide consisting of amino acid residues 28–

739 of SEQ ID NO;

7, the method comprising;

inoculating an animal with the soluble multimeric or heterodimeric cytokine receptor, wherein the soluble multimeric or heterodimeric cytokine receptor elicits an immune response in the animal to produce an antibody that specifically binds the soluble multimeric or heterodimeric cytokine receptor; and

isolating the antibody from the animal.

7. A cultured cell comprising an expression vector comprising the following operably linked elements;

a transcriptional promoter;

a DNA segment encoding a soluble cytokine receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO;

111; and

a transcriptional terminator and a second expression vector comprising;

a second transcription promoter;

a second DNA segment encoding a second soluble cytokine receptor polypeptide comprising amino acid residues 28–

739 of SEQ ID NO;

7; and

a second transcription terminator;

wherein the cell expresses the soluble cytokine receptor polypeptide encoded by the DNA segment and the second soluble cytokine receptor polypeptide encoded by the second DNA segment to form a soluble multimeric or heterodimeric cytokine receptor.

8. A method of producing a soluble multimeric or heterodimeric cytokine receptor comprising:

culturing a cell according to claim 7; and

isolating the soluble multimeric or heterodimeric cytokine receptor produced by the cell.

9. A composition comprising:

a soluble multimeric or heterodimeric cytokine receptor comprising a first soluble cytokine receptor polypeptide comprising amino acid residues 20–

519 of SEQ ID NO;

111 and a second soluble cytokine receptor comprising amino acid residues 28–

739 of SEQ ID NO;

7; and

a pharmaceutically acceptable vehicle.